Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Baxter
Fuji
Federal Trade Commission
QuintilesIMS
McKesson
Chubb
Accenture
Covington

Generated: June 25, 2018

DrugPatentWatch Database Preview

Vandetanib - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for vandetanib and what is the scope of vandetanib freedom to operate?

Vandetanib
is the generic ingredient in one branded drug marketed by Genzyme Corp and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vandetanib has one hundred and thirty-seven patent family members in forty-two countries.

Two suppliers are listed for this compound.
Summary for vandetanib
International Patents:137
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 96
Clinical Trials: 84
Patent Applications: 5,806
Formulation / Manufacturing:see details
DailyMed Link:vandetanib at DailyMed
Synonyms for vandetanib
(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine
2ivu
338992-00-0
4-(4-Bromo-2-fluoroanilino)-6-methoxy- 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl)methoxyquinazoline
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazoline
4-BROMO-2-FLUORO-N-[(4E)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLIN-4(1H)-YLIDENE]ANILINE
4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-
443913-73-3
68541-EP2298768A1
68541-EP2308855A1
913V733
A25648
AB0008635
AB01273969_04
AB01273969-01
AB01273969-02
AB1008463
ABP000873
AC-5251
AC1MIWRU
AJ-45811
AK106976
AKOS015902350
AN-3469
ANW-61824
AOB87780
AS-11067
AZD-6474
BC224441
BCPP000023
BDBM21
C22H24BrFN4O2
Caprelsa
Caprelsa (TN)
CAS-443913-73-3
CH 331
CH-331
CHEBI:49960
CHEMBL24828
cid_3081361
CS-0130
CTK8B9016
D06407
D0G6QF
DB05294
DMPC Cyclic Urea 1
DSSTox_CID_26681
DSSTox_GSID_46681
DSSTox_RID_81816
DTXSID1046681
EN002713
EX-A422
F9995-0087
FT-0656736
GNF-PF-2188
GTPL5717
HE069787
HE343618
HMS3244K03
HMS3244K04
HMS3244L03
HMS3654E11
HSDB 8198
HY-10260
I14-1942
KB-34269
Kinome_3316
LS-184394
MCULE-4705827953
MFCD07772346
MLS006011672
MolPort-005-942-399
N-(4-bromo-2-fluoro-phenyl)-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazolin-4-amine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
NCGC00167513-01
NCGC00167513-02
NCGC00167513-03
NCGC00167513-04
NSC-744325
NSC-760766
NSC744325
NSC760766
PubChem22460
QCR-37
Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-
RS0036
RT-016214
s1046
SC-23330
SCHEMBL9044
SMR002530472
SR-00000000462
SR-00000000462-2
ST2407381
SYN1090
Tox21_112511
Tox21_112511_1
UHTHHESEBZOYNR-UHFFFAOYSA-N
UNII-YO460OQ37K
V-9402
Vandetanib (JAN/INN)
Vandetanib (JAN/USAN/INN)
Vandetanib (Pan-TK inhibitor)
vandetanib (zd6474)
Vandetanib [INN]
Vandetanib [USAN:INN:BAN:JAN]
Vandetanib, Zactima, ZD6474
Vandetanib;7-((4-aminocyclohexyl)methoxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine
Vandetanib(Zactima),ZD6474/
Vandetinib
W-5356
YO460OQ37K
Zactima
Zactima, ZD6474
ZD 6474
ZD-64
ZD-6474
ZD6474
ZINC53683345

US Patents and Regulatory Information for vandetanib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for vandetanib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,548 Quinazoline derivatives as VEGF inhibitors ➤ Sign Up
6,414,148 Quinazoline derivatives and pharmaceutical compositions containing them ➤ Sign Up
6,673,803 Quinazoline derivatives and pharmaceutical compositions containing them ➤ Sign Up
6,897,210 Quinazoline derivatives and pharmaceutical compositions containing them ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for vandetanib

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
9 Finland ➤ Sign Up
2012015,C1244647 Lithuania ➤ Sign Up PRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217
2012000057 Germany ➤ Sign Up PRODUCT NAME: VANDETANIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
C/GB12/036 United Kingdom ➤ Sign Up PRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/749/001 20120217; UK EU/1/11/749/002 20120217
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Chinese Patent Office
Colorcon
Mallinckrodt
Baxter
Julphar
Moodys
QuintilesIMS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.